279 related articles for article (PubMed ID: 2083515)
1. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
Todd PA; Goa KL
Drugs; 1990 Oct; 40(4):583-607. PubMed ID: 2083515
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia.
Plosker GL; McTavish D
Drugs; 1995 Aug; 50(2):334-63. PubMed ID: 8521762
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
6. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.
McTavish D; Sorkin EM
Drugs; 1991 Jul; 42(1):65-89. PubMed ID: 1718686
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of medium-term treatment with simvastatin in primary hypercholesterolaemia.
Marnini P; Colombo F; Cattaneo R; Geroli L; Venco A
Int J Clin Pharmacol Res; 1992; 12(2):65-70. PubMed ID: 1428300
[TBL] [Abstract][Full Text] [Related]
8. Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Smit JW; Van Erpecum KJ; Portincasa P; Renooij W; Erkelens DW; Van Berge-Henegouwen GP
Gut; 1995 Nov; 37(5):654-9. PubMed ID: 8549941
[TBL] [Abstract][Full Text] [Related]
9. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Illingworth DR; Bacon S
Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Pietro DA; Alexander S; Mantell G; Staggers JE; Cook TJ
Am J Cardiol; 1989 Mar; 63(11):682-6. PubMed ID: 2646895
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia.
Smith DH; Neutel JM; Jankelow D; Myburgh DP
S Afr Med J; 1990 May; 77(10):500-3. PubMed ID: 2188379
[TBL] [Abstract][Full Text] [Related]
13. [Effects of simvastatin on plasma levels of lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia].
Caruzzo C; Uslenghi E; Varbella F; Caruzzo E; Marcolongo M; Brusca A
Minerva Cardioangiol; 1989 Dec; 37(12):509-15. PubMed ID: 2695857
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Lea AP; McTavish D
Drugs; 1997 May; 53(5):828-47. PubMed ID: 9129869
[TBL] [Abstract][Full Text] [Related]
15. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
16. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
17. Simvastatin and cholestyramine in the long-term treatment of hypercholesterolaemia.
Ytre-Arne K; Nordøy A
J Intern Med; 1989 Nov; 226(5):285-90. PubMed ID: 2681508
[TBL] [Abstract][Full Text] [Related]
18. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
Mol MJ; Erkelens DW; Gevers Leuven JA; Schouten JA; Stalenhoef AF
Atherosclerosis; 1988 Feb; 69(2-3):131-7. PubMed ID: 3279966
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
20. A 6-month trial of simvastatin (HMG-CoA reductase inhibitor) in the treatment of hypercholesterolaemia.
Steyn K; Weich HF; Vermaak WJ; Marais AD; Omar MA; Van Gelder AL; Fourie J; Kotze TJ; Stander I; Firth JC
S Afr Med J; 1991 Jun; 79(11):639-45. PubMed ID: 2047945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
